Pfizer and Qiagen Sign Second Companion Diagnostics Deal
By Heather Cartwright
Pharma Deals Review: Vol 2011 Issue 8 (Table of Contents)
Published: 31 Aug-2011
DOI: 10.3833/pdr.v2011.i8.1527 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
Qiagen has signed a second companion diagnostics deal with Pfizer, this time to develop a molecular test for use with Pfizer’s investigational compound dacomitinib (PF-00299804), which is in Phase III development for non-small-cell lung cancer (NSCLC)...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS